EGFR and non-small cell lung carcinoma: As the brain is a known metastatic site of NSCLC expressing EGFR mutations and many TKIs are substrates of efflux transporters functioning at the blood–brain barrier, the influence of BCRP and P-gp on the brain penetration of [O-methyl-11C]erlotinib has been evaluated in various studies.